News
RCDTF
60.00
NaN%
--
Recordati Sells Treasury Shares to Satisfy Stock Option Exercises
TipRanks · 06/05 16:24
Recordati’s Main Shareholder Backs CVC‑Led Bid to Delist Drugmaker from Euronext Milan
TipRanks · 05/27 19:32
Recordati Accelerates Performance Share Plan Ahead of Delisting Bid
TipRanks · 05/27 18:23
Respighi BidCo concert parties lift stakes in Recordati during takeover bid
TipRanks · 05/27 17:14
Bid Consortium Tightens Grip on Recordati With Fresh Share Purchases
TipRanks · 05/22 18:12
Respighi BidCo launches premium tender offer to take Recordati private and delist from Euronext Milan
TipRanks · 05/22 06:39
CVC and GBL launch €10.7bn bid to take Recordati private
TipRanks · 05/22 05:28
Recordati reports Q1 results
Seeking Alpha · 05/13 12:47
Recordati lifts Q1 revenues on rare disease strength and advances key pipeline programs
TipRanks · 05/12 17:07
Recordati Sells Treasury Shares to Satisfy Stock Option Exercises
TipRanks · 05/06 16:58
Recordati Publishes Voting Summary from 29 April 2026 Shareholders’ Meeting
TipRanks · 04/30 14:12
Recordati Lifts Dividend, Renews Buyback Powers and Overhauls Governance
TipRanks · 04/29 11:10
Kepler Capital Remains a Buy on Recordati Industria Chimica e Farmaceutica SPA (0KBS)
TipRanks · 04/23 01:35
Recordati Publishes Candidate Lists for New Board of Statutory Auditors Ahead of April Meeting
TipRanks · 04/08 16:37
Recordati details March buy-back trades and stock option-related treasury share sales
TipRanks · 04/07 17:05
Recordati Extends Deadline and Lowers Threshold for Board of Statutory Auditors Slates
TipRanks · 04/04 16:52
Recordati Publishes 2025 Financial and Governance Reports Ahead of April Shareholders’ Meeting
TipRanks · 04/01 19:32
Kepler Capital Remains a Buy on Recordati Industria Chimica e Farmaceutica SPA (0KBS)
TipRanks · 03/28 04:55
Recordati Publishes Documentation for April 2026 Shareholders’ Meeting
TipRanks · 03/27 19:24
Recordati Confirms CVC’s Non-Binding Interest in Potential Takeover Bid
TipRanks · 03/26 13:52
More
Webull provides a variety of real-time RCDTF stock news. You can receive the latest news about Recordati Industria Chimica Ef through multiple platforms. This information may help you make smarter investment decisions.
About RCDTF
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.